Combined therapy with ipratropium and theophylline in asthma

Ann Allergy. 1984 Feb;52(2):90-3.

Abstract

Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg) were administered to 24 asthmatics in a randomized double-blind placebo controlled trial. The combination of these agents produced additive bronchodilation for up to two hours, with a 23 percent maximal increase in FEV1. This regimen promises to be safe, effective therapy for patients with asthma.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Asthma / diagnosis
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Atropine Derivatives / therapeutic use*
  • Bronchodilator Agents / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Forced Expiratory Volume
  • Humans
  • Ipratropium / therapeutic use*
  • Male
  • Maximal Midexpiratory Flow Rate
  • Middle Aged
  • Theophylline / therapeutic use*

Substances

  • Atropine Derivatives
  • Bronchodilator Agents
  • Theophylline
  • Ipratropium